Traditional Chinese medicine for the hematological toxic reaction caused by highly active antiretroviral therapies (HARRT): a randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001260

Enrollment

Unknown

Registered

2011-03-16

Start date

2009-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, hematological toxic reaction

Interventions

TCM:Basic treatment+TCM

Control:Basic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with hematological toxic reaction caused by HARRT; 2. aged 18 to 65 years old; 3. Patients did not receive medicine that interfere the observation of this trial in last month; 4. Patients voluntarily signed the informed consent; 5. Patients receiving no blood transfusion in last 4 months.

Exclusion criteria

Exclusion criteria: 1. Patients with grade III of hematological toxic reaction according to the WHO anti-tumor drug classification and needing change therapy; 2. Pregnant or lactating women, or women who have birth plan; 3. Patients with severe heart, liver or kidney disease or psychological disease including severe hysteria; 4. Patients receiving other TCM therapy; 5. Patients with other hematological disease that could confound the results or increase risk.

Design outcomes

Primary

Measure	Time frame
Count of blood cells;	—

Secondary

Measure	Time frame
Quality of Life;	—

Countries

China

Contacts

Public ContactYu Mao

myqmz58@yahoo.com+86 13552484984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026